Thank you for Subscribing to Med Tech Business Review Weekly Brief
Hugh Sims Hilditch, Executive ChairmanWhat gap exists in glucose monitoring for prediabetes and early Type 2 diabetes?
Anytime CT3 has been voted the Best CGM in Europe by European MedTech Business Magazine — recognition that reflects a genuinely historic milestone in the fight against one of the UK and Europe’s most urgent preventable health crises. The Yuwell Anytime CT3 is a new continuous glucose monitor in the UK designed, clinically proven and peer reviewed for the early Type 2 market. Feedback from researchers demonstrates that the CT3 is also an ideal device for the management of prediabetes. An estimated 14 million people in the UK and 18–25 million across Europe are living with prediabetes or early-stage Type 2 diabetes — the majority undiagnosed, the majority unaware and the majority currently beyond the reach of conventional CGM systems designed for insulin-dependent patients. Anytime CT3 exists to change that.
Anytime CT3’s CGM system is designed to expand access to continuous glucose monitoring through a rechargeable transmitter that supports long-term use and early intervention. Across Europe, fewer than 20 per cent of the 18 to 25 million people living with early-stage type 2 diabetes currently use CGM, while conventional systems contribute to growing electronic waste.
Advancing CGM: Clinically Proven Accuracy Meets Sustainable, Accessible Innovation
How does Anytime CT3 combine clinical accuracy with accessibility and long-term sustainability?
Anytime CT3 addresses these challenges with its rechargeable CT3 transmitter, which offers a two-year lifecycle to reduce waste and lower barriers to sustained use.
Designed for accuracy and aligned with ADA guidelines, the system demonstrates strong clinical performance, including a 0.91 correlation with traditional blood glucose testing. Critically, the Yuwell Anytime CT3 is the subject of an independent peer-reviewed clinical study published in the British Journal of Nursing (Lancaster et al, 2026), which confirmed a Mean Absolute Relative Difference (MARD) of 6.9% — in patients with early Type 2 diabetes below the 10 per cent clinical benchmark widely used in CGM accuracy assessment.
This peer-reviewed validation is central to Anytime CT3’s market positioning: the CT3 is not simply a lower-cost alternative — it is a clinically proven device.
As an executive chairman Hugh Sims Hilditch notes, “the system is intended to make CGM more accessible while maintaining environmental responsibility.”
-
For the first time, there is a clinically proven, peer-reviewed CGM designed specifically for early Type 2 diabetes — affordable, sustainable and built for the 14 million people in the UK who need it most.
Anytime CT3 reinforces its sustainability edge with measurable impact: user experience remains central with studies showing high satisfaction of 99 per cent found it easy to use, all rated it safe and 99 per cent could apply it independently is supported by real-world data across diverse patient groups. The rechargeable CT3 transmitter generates 126.9 kg CO₂e over a two-year lifecycle, significantly reducing electronic waste compared to disposable CGM systems. This extended lifecycle not only lowers environmental footprint but also strengthens long-term usability and cost efficiency.
Real-world behaviour change data from an independent study with Bluecrest Wellness — the UK’s largest provider of health assessments — further supports the clinical case. Participants wearing the CT3 for 14 days showed a meaningful reduction in HbA1c from 43.0 to 41.2 mmol/mol over a three-month follow-up period, with participants consistently describing the experience as ‘empowering’ and ‘motivating’.
“I decided to buy myself a Yuwell Anytime continuous glucose monitor. Very quickly, it became obvious where I was going wrong. I cut out bread from my diet for three months and booked myself in for a repeat HbA1c. It had fallen below the pre-diabetic range. I found wearing the Anytime empowering and motivating. It allowed me to make informed changes to my diet which produced significant improvement in my projected health outcomes,” says Dr Dawn Harper, MBBS MRCP DCH DFFP, NHS GP, author and broadcaster.
From Sensor Accuracy to Smart Monitoring
Why does reusable CGM design matter for access, adherence, and ongoing monitoring?
Data shows 92.5 per cent of users complete the full sensor wear cycle. A Latvia post-market study found participants spent over 72 per cent of time within the 70–180 mg/dL target range, with stable glucose and minimal spikes. The CT3 sensor supports flexible placement, with only 0.5 per cent variation, confirming consistent accuracy and reproducibility.
Anytime CT3 addresses an access gap in early-stage type 2 diabetes and prediabetes with a rechargeable CGM model that reduces cost and waste. At £40 + VAT per 14-day sensor and £30 + VAT for the reusable transmitter — which lasts up to two years — the CT3 offers a total cost of ownership significantly below that of leading CGM alternatives, making sustained use genuinely accessible for the first time to the 14 million people in the UK currently at the prediabetes stage. Real-time feedback drives behavior change, while NHS integration enables scalable, clinically credible adoption.
As a long-standing supplier, the company has secured a place for the Yuwell Anytime CT3 system on the Wales procurement frameworks for insulin pumps and continuous glucose monitoring — meaning that NHS trusts and integrated care systems in both nations now have a straightforward, compliant and procurement-barrier-free route to access this technology.
Expanding the Reach of CGM: Clinically Validated, Connected and Built for Earlier Intervention
In what way does Anytime CT3 support earlier intervention and connected glucose care?
This framework positioning signals rigorous clinical and regulatory validation and — more importantly — enables clinicians to adopt CGM at the point where it can make the greatest difference: earlier in the Type 2 and prediabetes pathway, shifting care from reactive management to proactive, data-driven intervention.
The system has open API integration capability for remote monitoring. It is compatible with third-party systems such as Glooko and Apple Watch, enabling the movement of data across health platforms and providing doctors and patients with more comprehensive views of glucose trends.
As Europe’s voted best CGM, Anytime CT3 is doing something that has never been done before: bringing a clinically proven, peer-reviewed, affordable and sustainable continuous glucose monitor to the people who need it most. It can support the millions of people living with prediabetes and early Type 2 diabetes who until now have had no device designed with them in mind. By combining the clinical rigour of peer-reviewed evidence, the commercial accessibility of a genuinely affordable price point and the environmental responsibility of a reusable transmitter with a two-year life, the Anytime CT3 is not simply a better CGM. It is the right CGM for the right moment, serving a market that the rest of the industry has not yet reached.
For the first time, there is a clinically proven, peer-reviewed CGM designed specifically for early Type 2 diabetes — affordable, sustainable and built for the 14 million people in the UK who need it most.
Evaluating Continuous Glucose Monitoring Systems for Scalable, Early Intervention Care
Continuous glucose monitoring has moved beyond a specialist tool for insulin-dependent patients into a broader instrument for early intervention, behavioural insight and long-term metabolic management. Across Europe, a significant proportion of individuals in early-stage type 2 diabetes remain outside structured monitoring frameworks, limiting the ability of clinicians to influence progression through timely, data-informed decisions. This gap has shifted attention toward systems that extend access without compromising clinical reliability.
Adoption challenges tend to emerge from three intersecting pressures. Device economics and sustainability increasingly influence procurement decisions, particularly in public health systems where long-term cost and environmental impact are scrutinised alongside clinical value. Traditional CGM models, often reliant on frequent sensor replacement and disposable components, introduce recurring costs and waste that scale quickly across large patient populations. Decision-makers now prioritise solutions that reduce lifecycle burden while maintaining consistent performance.
Clinical confidence remains another decisive factor. Monitoring systems must demonstrate not only accuracy against established glucose measurement standards but also stability across varied patient conditions and wear scenarios. Real-world consistency, rather than controlled trial performance alone, determines whether clinicians can rely on data for treatment adjustments. Systems that support reproducibility across placement sites and maintain low variability in readings strengthen their role in guiding therapeutic decisions, particularly in patients with multiple comorbidities or fluctuating glycaemic profiles.
User engagement completes the equation. Passive data collection offers limited value if patients do not translate insights into daily behavioural changes. Effective systems encourage active interaction by presenting data in a way that is both immediate and actionable, allowing users to connect lifestyle choices with measurable outcomes. Frequent data capture, intuitive interfaces and timely alerts contribute to sustained adherence, which in turn reinforces clinical effectiveness. High completion rates of sensor wear cycles often signal that a system has successfully aligned usability with patient routines.
Against this backdrop, Anytime CT3 presents a model that aligns closely with these evolving expectations. Its approach centres on extending access to continuous monitoring earlier in the diabetes journey while addressing practical constraints that have historically limited adoption. The rechargeable transmitter design, capable of extended use over multiple years, directly reduces waste and recurring replacement costs, supporting both economic and environmental considerations at scale. Clinical validation demonstrates strong alignment with traditional glucose measurement methods, while real-world studies indicate sustained time within target glucose ranges and low variability, even among complex patient groups.
The system’s emphasis on usability is evident in high rates of independent sensor application and consistently positive user feedback, indicating that design simplicity translates into adherence. Continuous data capture paired with real-time feedback enables users to interpret glucose trends in relation to daily activities, encouraging proactive management rather than episodic checking. Integration with broader digital health ecosystems and support for remote monitoring further positions it within contemporary care models, where data continuity across platforms is essential.
Anytime CT3’s standing within established healthcare frameworks, including its presence in structured procurement pathways, reinforces its credibility for institutional adoption. Its combination of sustained device performance, accessible design and integration capability reflects a solution calibrated not only for individual patient benefit but also for system-wide scalability, making it a compelling choice for organisations aiming to expand continuous glucose monitoring into earlier stages of care.
...Read more
Glucose Monitoring Systems in Europe Info
Q1
Why is Anytime CT3 recognized among top providers of Glucose Monitoring Systems in Europe?
Anytime CT3 has gained attention in the Glucose Monitoring Systems in Europe market because it focuses on making glucose monitoring more accessible, responsive and adaptable to modern patient needs. The company emphasizes continuous innovation in diabetes management technologies while maintaining a patient-centered approach to usability and data accessibility. Its systems are designed to support faster monitoring decisions and more consistent glucose tracking across everyday care settings. By aligning technology development with practical clinical requirements, Anytime CT3 strengthens its position within the evolving European glucose monitoring landscape.
Q2
What differentiates Anytime CT3 from other companies in this field?
A major differentiator is the company’s focus on integrating usability with reliable glucose monitoring performance. Anytime CT3 develops Glucose Monitoring Systems in Europe with attention to real-world patient experiences, including ease of use, monitoring consistency and device accessibility. Rather than positioning technology as a standalone product, the company supports broader diabetes management workflows that help users and healthcare professionals interpret glucose trends more efficiently. Its commitment to responsive product development and adaptable monitoring solutions allows it to address changing expectations across European healthcare environments.
Q3
How does Anytime CT3 support healthcare providers and users?
Strong technical support and ongoing engagement form an important part of the company’s approach. Anytime CT3 works to ensure that its Glucose Monitoring Systems in Europe remain practical for both healthcare professionals and patients by prioritizing training, usability and streamlined implementation. The company focuses on reducing complexity in glucose tracking while helping users maintain confidence in day-to-day monitoring activities. This support-oriented model helps improve device adoption and contributes to more consistent glucose management experiences across clinical and personal care settings.
Q4
How do Anytime CT3’s solutions create value in diabetes management?
Value creation comes from combining monitoring reliability with user-focused functionality. Anytime CT3 develops Glucose Monitoring Systems in Europe that help support timely glucose tracking, clearer data interpretation and more efficient diabetes management routines. Its technologies are intended to simplify monitoring processes while supporting better visibility into glucose fluctuations throughout the day. By balancing technological advancement with usability, the company helps healthcare organizations and users integrate glucose monitoring more naturally into ongoing care management strategies.
Q5
What role does innovation play in Anytime CT3’s growth strategy?
Innovation remains central to the company’s long-term direction. Anytime CT3 continues investing in monitoring technologies that improve performance, usability and patient engagement within the Glucose Monitoring Systems in Europe sector. The company focuses on solutions that respond to changing healthcare expectations, including the demand for more connected, responsive and data-driven diabetes management tools. Its emphasis on technology refinement and continuous product improvement supports both clinical efficiency and user convenience in increasingly digital healthcare environments.
Q6
Why is Anytime CT3 relevant to the future of glucose monitoring in Europe?
European healthcare systems continue prioritizing preventive care, chronic disease management and patient-centered monitoring solutions, which increases the importance of advanced glucose technologies. Anytime CT3 addresses these priorities by developing Glucose Monitoring Systems in Europe that support accessibility, monitoring continuity and practical integration into everyday diabetes care. The company’s focus on adaptable technology, monitoring accuracy and user experience positions it as a relevant contributor to the future direction of glucose management solutions across the region.
